Sharing our review article: “Dulaglutide in the Era of Tirzepatide and Semaglutide: Reaffirming Its Role in Contemporary Cardiometabolic Care.” In an era where semaglutide and tirzepatide have raised expectations for HbA1c and weight reduction, our article revisits an important clinical question: does dulaglutide still have a meaningful role? We highlight that dulaglutide remains a complementary, not obsolete, incretin-based therapy—supported by robust cardiovascular outcome evidence, especially from REWIND, practical tolerability, simple once-weekly use, and easier attainment of therapeutic dosing in routine care. Its relevance is particularly strong for primary cardiovascular prevention, older adults, patients intolerant to more potent incretin therapies, and cost-sensitive or resource-limited settings. This article may interest clinicians seeking a pragmatic framework for incretin selection beyond potency alone—balancing efficacy, safety, adherence, affordability, and access. Link to read: link.springer.com/article/10… Note: At the time of writing, generic semaglutide was not available in India; however, our article does not specifically analyze generic semaglutide.